Interim Report, 1 January – 31 March 2013*
Q1 2013 (January-March) · Net turnover totalled SEK 282.6 million (SEK 137.9 m). · The profit/loss after tax was SEK 77.6 million (SEK -37.7 m). · Basic and diluted earnings per share totalled SEK 2.48 (SEK -1.21). · The cash flow from operating activities amounted to SEK -19.1 million (SEK -45.8 m), while liquid assets and short-term investments totalled SEK 264.4 million (SEK 485.6 m) at the period end. Significant events during Q1 · Collaboration agreement was reached for phase II combination trials with simeprevir, TMC647055 and IDX719. · Registration